PRESS RELEASE

The HAS confirms the efficiency of Ziwig Endotest® for the diagnosis of endometriosis

9th of January 2024 - Ziwig, a French company at the forefront of biotechnology and women's health, announces that the French National Authority for Health (HAS) has confirmed the efficacy of the innovative salivary test for diagnosing endometriosis, Ziwig Endotest®. This test, which has already been awarded the Prix Galien and been the subject of publication in the New England Journal of Medicine Evidence, marks a major advance in the diagnosis of this complex condition.

A significant step towards diagnosing endometriosis

Yahya El Mir, founder of Ziwig, said: "This is an important moment for women suffering from endometriosis, a disease that is often difficult to diagnose. Ziwig Endotest® promises a reliable, rapid and non-invasive diagnosis, dramatically reducing diagnostic wandering for thousands of patients."

Cutting-edge technology for accurate diagnosis

Ziwig Endotest® stands out as a non-invasive approach due to its breakthrough technology combining RNA analysis and Artificial Intelligence. This technology offers an alternative to traditional diagnostic processes, which are often lengthy, operator-dependent and invasive, and provides fast and reliable results.

Future prospects in medical research

This recognition by the HAS is a testimony to the disruptive potential of Ziwig's technology, which is not limited to endometriosis. Current projects, including the GynARN study (https://ziwig.com/wp-content/uploads/2023/12/CP-GYN-ARN-V2-ENG.pdf), aim to develop salivary diagnostics for other gynaecological pathologies, as well as in the fields of oncology and neurology, based on this same innovative technology.

Commitment to medical excellence and accessibility

Ziwig is firmly committed to providing relevant and accessible healthcare solutions. It will therefore continue to work with health authorities to ensure wider and safer access to Ziwig Endotest®. The aim is to make this test available as quickly as possible to all eligible women who need it.

Indications

Ziwig Endotest® is intended for patients aged between 18 and 43 with symptoms suggestive of endometriosis and with normal or equivocal imaging results, prior to empirical medical treatment.

It is also intended for patients with persistent symptoms suggestive of endometriosis despite medical treatment and when the results of the imaging examination are normal or equivocal.

Ziwig Endotest® is a prescription medical device. It has obtained the CE mark.

About Ziwig Endotest®

Ziwig Endotest® is a major advance in the diagnosis of endometriosis. It represents the culmination of pioneering research in biotechnology (RNA) and artificial intelligence. This innovation is the result of a total commitment to improving the lives of patients faced with this complex disease.

- Ziwig Endotest® is an in vitro diagnostic device reserved for professional use for the diagnosis of endometriosis using a saliva sample.
- It is intended for female patients, aged between 18 and 43, presenting with signs suggestive of endometriosis as part of a diagnostic pathway coordinated by a healthcare professional authorised to make a diagnosis.
- Patients must not be pregnant or have a history of cancer or HIV infection. The use of oestrogen or progesterone does not affect the results of the test.

About Ziwig

Ziwig is an innovative French biotech specialising in salivary RNA analysis and AI. It operates as an ecosystem at the crossroads of several medical, scientific and digital disciplines. It is strongly committed to transforming healthcare systems towards more effective, more humane and more accessible precision medicine.

Press Contacts:
Finn Partners
sante@finnpartners.com
Aurélia Adloff - +33 6 89 38 94 70
Véronique Simon-Cluzel - +33 6 68 86 32 30